Ipsen recruits Steven Hildemann as CMO; Eli Lilly offers two more low-cost insulin options
→ After losing their CEO last month, Ipsen — who’s grappling with an FDA hold after safety concerns emerged from late-stage studies of its lead rare disease drug palovarotene — has tapped former Merck Serono exec Steven Hildemann as EVP, chief medical officer, head of global medical affairs and pharmacovigilance. During his time at Merck, Hildemann served as CMO and SVP and head of global medical affairs and patient safety. His previous experience spans Merck/Schering Plough, Amgen and Pfizer/Pharmacia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.